2-[(2-Nitro-9H-fluorene-9-ylidene)methyl]phenol

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 2-[(2-Nitro-9H-fluorene-9-ylidene)methyl]phenol
• 英文别名: 2-[(Z)-(2-nitrofluoren-9-ylidene)methyl]phenol
• 化学式: C20H13NO3
• 分子量: 315.3
• InChiKey: PEYKRJBXACUOOB-WQRHYEAKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO<br/>[FR] AGONISTE DE BAX, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
  申请人：UNIV EMORY

  公开号：WO2013028543A1

  公开（公告）日：2013-02-28

  The disclosure relates to BAX activators and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.

  本公开涉及BAX激活剂及其治疗用途。在某些实施例中，本公开涉及治疗或预防癌症的方法，例如肺癌，包括向需要的受试者施用本公开的化合物或药学上可接受的盐所述的药物组合的治疗有效量。
• BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO
  申请人：Deng Xingming

  公开号：US20140178374A1

  公开（公告）日：2014-06-26

  The disclosure relates to BAX activators and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.

  该披露涉及BAX活化剂及其治疗用途。在某些实施例中，该披露涉及治疗或预防癌症的方法，例如肺癌，包括向需要该治疗的受试者施用含有此处披露的化合物或药学上可接受的盐的药物组合物的治疗有效量。
• COMPOUNDS AND THERAPEUTIC USES
  申请人：Unity Biotechnology, Inc.

  公开号：US20170281649A1

  公开（公告）日：2017-10-05

  Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.
• US9040567B2
  申请人：——

  公开号：US9040567B2

  公开（公告）日：2015-05-26
• US9402850B2
  申请人：——

  公开号：US9402850B2

  公开（公告）日：2016-08-02